- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03900520
Pneumonia Research and Vaccine Impact League (PREVAIL)
Evaluating Pneumococcal Conjugate Vaccine (PCV) Impact on Pneumonia and Pneumococcal Carriage Outcomes in India in Children 1-35 Months in India: Pneumonia Research and Vaccine Impact League
Study Overview
Status
Conditions
Detailed Description
Streptococcus pneumoniae (pneumococcus) is the leading cause of severe respiratory disease and death in young children, and is also responsible for other serious diseases such as meningitis and sepsis. Global disease burden models for the year 2015, estimate that 20 percent of global childhood pneumococcal deaths occurred in India. Data from India indicate that available pneumococcal conjugate vaccines (PCV) include serotypes that account for 66 to 74 percent of invasive pneumococcal disease (IPD) in young children. The 2017 PCV launch into the national immunization schedule in selected high-burden states was poised to successfully combat the pneumococcal disease burden in the country once scale-up of vaccine coverage takes place. The Government of India has recommended robust evaluation of PCV impact to facilitate national rollout and sustained use of PCV.
This study aims to evaluate the impact of PCV introduction to the national immunization program. The investigators propose to quantify the impact of PCV on pneumonia and other acute respiratory infections resulting in hospitalization and on community carriage of pneumococci. Hereafter, in reference to the proposed study, the investigators use the term 'pneumonia' to denote to a group of physician-based diagnoses representing a range of acute respiratory illness including pneumonia. Specifically, the investigators propose to measure differences in the proportion of pneumonia hospitalizations in children 1-35 months colonized with vaccine-serotype (VT) pneumococcus, as well as differences in VT pneumococcal nasopharyngeal (NP) colonization in the community, comparing children enrolled at sites where PCV has been introduced (PCV sites) to children at sites where PCV has not yet been introduced (non-PCV sites). The health economic aims will consist of assessing the cost of illness of pneumococcal disease, and economic cost of pneumococcal disease and pneumonia hospitalization. The investigators have designed this portfolio of PCV impact evaluations within the context of PCV introduction and rollout in six selected states in India, mindful of the need for baseline data, the staggered plan for PCV roll-out, variance of cost-generating events, and the inherent biases of non-interventional studies with outcomes that are not specific for pneumococcal disease and that may be subject to secular trends and possible confounders. The study sites are located in New Delhi and within three of the six states that were included in the PCV rollout plan starting in 2017. The investigators plan this as a two-year study that will include data from both PCV sites and non-PCV sites, the comparison of which will allow an assessment of vaccine impact. Active study sites will be located in Delhi; Agra in Uttar Pradesh state (non-PCV-using); Bhopal in Madhya Pradesh state; and Jaipur in Rajasthan state (PCV-using). Community enrollment will take place in two demographic survey sites in Bhopal and Delhi, and economic assessment will take place in four hospital sites. Sites will use a common protocol to identify and recruit children, obtain nasopharyngeal swabs for colonization studies, and run validated laboratory tests. A reference laboratory will provide pneumococcal serotyping results, nasopharyngeal quantification of pneumococcus, and provide site laboratory oversight.
These data will provide evidence to policy makers on changes in pneumococcal disease burden in young children, pneumococcal community transmission changes as a result of PCV introduction, that can help policy makers support, optimize, and advocate for the expansion of the PCV immunization program in India and in other countries.
The primary objectives of PREVAIL are as follows:
- Quantify the difference in the proportion of hospitalized pneumonia cases 1-35 months of age carrying a vaccine-type pneumococcus in the nasopharynx in cases enrolled at sites that have introduced PCV into the national immunization program compared to cases enrolled at sites that have not introduced PCV
- Quantify the difference in the proportion of children in the community 1-35 months who are colonized with vaccine-type pneumococcus enrolled at a site that has introduced PCV into the national immunization program compared to the proportion of children colonized with vaccine-type pneumococcus enrolled at a site that has not introduced PCV
- Determine the overall economic impact of PCV by: (i) Estimating the total cost of hospitalized pneumonia in children 1-35 months from the healthcare system and household perspectives; and (ii) Estimating the proportion of households facing catastrophic health spending and medical impoverishment from out-of-pocket health expenses due to hospitalized pneumonia in children 1-35 months.
Secondary objectives are evaluated within each of the four groups, and are;
- Assess the difference in mortality and occurrence of illnesses within 3 months of hospital discharge among children aged 1-35 months presenting with pneumonia in PCV-using sites compared to children at non-PCV sites.
- Quantify the difference in proportion among hospitalized cases aged 1-35 months with alveolar consolidation detected on radiography in PCV-using sites compared to children at non-PCV sites.
- Quantify the difference in proportion among hospitalized cases aged 1-35 months with hypoxemia (oxygen saturation<90%) in PCV-using sites compared to children at non-PCV sites.
Quantify the difference in proportion of hospitalized cases aged 1-35 months that are vaccinated at PCV-using sites (indirect cohort method to assess vaccine effectiveness) between the following groups:
- Carrying a VT vs. carrying a non-VT serotype
- With vs. without alveolar consolidation
- With vs. without hypoxemia
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Anita Shet, MD, PhD
- Phone Number: 410-502-2629
- Email: ashet1@jhu.edu
Study Locations
-
-
-
New Delhi, India
- Maulana Azad Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
There are three cohorts/groups that are recruited:
PREVAIL-Pneumo: Cases aged 1-35 months of age hospitalized with physician-diagnosed pneumonia or lower respiratory tract infection.
PREVAIL-Community: Children 1-35 months of age residing in the community with no systemic illness and randomly selected for inclusion into this group
PREVAIL-Econ: A subset of cases enrolled into the PREVAIL-Pneumo study
Description
PREVAIL-Pneumo:
Inclusion criteria:
- Age 1-35 months
- Admitting diagnosis is pneumonia or lower respiratory tract illness/infection Written informed consent obtained from parent or legally authorized representative
Exclusion criteria:
- Discharged as an PREVAIL case in the last 90 days
PREVAIL-Community:
Inclusion criteria:
- Age 1-35 months with no systemic illness (mild respiratory illness is not an exclusion criteria)
- Written informed consent obtained from parent or legally authorized representative
Exclusion criteria:
- Known underlying serious disease (e.g., congenital heart diseases, immunodeficiency disorders, sickle cell anemia etc.) which may negatively influence the participant's ability to participate in the study
PREVAIL-Econ:
Inclusion criteria:
- Currently enrolled into the PREVAIL study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Pneumonia group (PREVAIL-Pneumo)
Children aged 1-35 months with pneumonia or lower respiratory tract infection hospitalized or recommended for hospitalization
|
Community group (PREVAIL-Community)
Children aged 1-35 years living in the community with no known systemic illness
|
Economic group (PREVAIL-Econ)
PREVAIL-Pneumo-enrolled children hospitalized for pneumonia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pneumonia colonized by vaccine-type Streptococcus pneumoniae
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
PREVAIL-Pneumo: Proportion of children with physician-diagnosed pneumonia that are colonized in the nasopharynx with 'vaccine-type' pneumococcus among sites where PCV has been introduced compared to sites where PCV has not been introduced (includes 13 serotypes included in the 13-valent pneumococcal conjugate vaccine)
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Community carriage of vaccine-type Streptococcus pneumoniae
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
PREVAIL-Community: Proportion of community children that are colonized in the nasopharynx with 'vaccine-type' pneumococcus enrolled at a site that has introduced PCV into the NIP compared to children enrolled at a site that has not introduced PCV (includes 13 serotypes included in the 13-valent pneumococcal conjugate vaccine)
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Pneumonia and IPD cost of illness
Time Frame: 1 years (1 year period mentioned refers to the duration of the proposed study in total)
|
PREVAIL-Econ: Determine the overall economic impact of PCV, including direct and indirect costs, both during hospitalization and longer-term expenditures at 3 months post hospitalization
|
1 years (1 year period mentioned refers to the duration of the proposed study in total)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pneumonia-Related Occurance of Illness
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Difference in occurrence of illnesses within 3 months of hospital discharge among children 1-35 months presenting with pneumonia at sites that have introduced PCV into the national immunization schedule versus cases enrolled at sites that have not introduced PCV.
(3 months refers to the duration each patient would be followed up for following discharge from the hospital)
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Pneumonia-Related Mortality
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Difference in mortality within 3 months of hospital discharge among children 1-35 months presenting with pneumonia at sites that have introduced PCV into the national immunization schedule versus cases enrolled at sites that have not introduced PCV.
(3 months refers to the duration each patient would be followed up for following discharge from the hospital)
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Radiographic pneumonia
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Proportion of children with primary-end point pneumonia detected on radiography, at sites that have introduced PCV into the national immunization schedule versus cases enrolled at sites that have not introduced PCV.
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Hypoxic Pneumonia
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Proportion of children with hypoxemic (oxygen saturation<90 percent) among hospitalized pneumonia cases 1-35 months at sites that have introduced PCV versus cases enrolled at sites that have not introduced PCV.
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Vaccine Effectiveness
Time Frame: 2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Proportion of hospitalized cases 1-35 months that are vaccinated in PCV-using sites (indirect cohort method to assess vaccine effectiveness) between the following groups: (1) Carrying a VT vs. carrying a non-VT serotype, (2) With vs. without alveolar consolidation, (3) With vs. without hypoxemia.
|
2 years (2 year period mentioned refers to the duration of the proposed study in total)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anita Shet, MD, PhD, Johns Hopkins Bloomberg School of Public Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11740
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Department of Health and Human ServicesNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States